SynthesisMedicine2016
Vitamin D Receptor Polymorphism and Breast Cancer Risk: A Meta-Analysis.
Synthesis in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Assessing the role of vitamin D in the prevention and management of chronic rhinosinusitis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis.BMC cancer · 2020Pooled it
- Vitamin D-induced mechanisms in cancer prevention and therapy: Recent advances and future opportunities.Animal models and experimental medicine · 2025Review
- Vitamin D in Cancer Prevention and Treatment: A Review of Epidemiological, Preclinical, and Cellular Studies.Cancers · 2024Review
- Vitamin D receptor gene polymorphisms and risk of breast cancer in Iranian women.Annals of medicine and surgery (2012) · 2022Article
- Assessment the effect of vitamin D supplementation on plasma vitamin D levels, inflammation, and oxidative stress biomarkers based on vitamin D receptor genetic variation in breast cancer survivors: a protocol for clinical trial.Journal of health, population, and nutrition · 2021Article
- Association of Vitamin D receptor gene variations with Gastric cancer risk in Kashmiri population.Molecular biology reports · 2021Article
- Vitamin D in Triple-Negative and BRCA1-Deficient Breast Cancer-Implications for Pathogenesis and Therapy.International journal of molecular sciences · 2020Review
- Vitamin D Status and Association ofNutrients · 2019Article
- Vitamin D Receptor Gene Polymorphism: Association with Susceptibility to Early-Onset Breast Cancer in Iranian, BRCA1/2-Mutation Carrier and non-carrier Patients.Pathology oncology research : POR · 2018Article
- Association of low penetrance vitamin D receptor Tru9I (rs757343) gene polymorphism with risk of premenopausal breast cancer.The Journal of international medical research · 2018Article
- Vitamin D Receptor Signaling and Cancer.Endocrinology and metabolism clinics of North America · 2017Review
- Vitamin D and Breast Cancer: Latest Evidence and Future Steps.Breast cancer : basic and clinical research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective was to perform a meta-analysis to summarize the available evidence from prospective nested case-control studies on the association of vitamin D receptor (VDR) polymorphism and the risk of breast cancer.We searched PubMed, ISI web of science, EMBASE, and reference lists for included articles. Study specific odds ratios (ORs) and 95% confidence intervals (CIs) were pooled by using fixed-effect or random-effects models.Eight studies were included in the meta-analysis. There were no association between Fok1 gene allele contrast f versus F (OR: 0.859; 95%CI: 0.685-1.079), ff versus FF (OR: 0.893; 95%CI: 0.763-1.045), recessive models ff versus FF+Ff (OR: 0.932; 95%CI: 0.796-1.092), and dominant models ff+Ff versus FF (OR: 0.899; 95%CI: 0.780-1.037). The estimated VDR polymorphism showed no significant association between Bsm1, Taq1, Apa1 polymorphism, and breast cancer risk. In the Caucasian ethnic subgroup, no association was found between allele contrast, recessive models, and dominant models on Fok1, Bsm1 polymorphism, and breast cancer risk.VDR polymorphism (Fok1, Bsm1, Taq1, and Apa1) were not associated with the risk of breast cancer in the general population as well as Caucasian population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.